Analyst Price Targets — ATRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 8:49 am | — | Canaccord Genuity | $13.00 | $9.93 | TheFly | Atara Biotherapeutics upgraded to Buy from Hold at Canaccord |
| January 13, 2026 6:37 pm | — | New Street | $6.00 | $4.42 | TheFly | Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) |
| December 19, 2025 11:28 am | — | Canaccord Genuity | $25.00 | $17.23 | TheFly | Atara Biotherapeutics price target raised to $25 from $17 at Canaccord |
| November 13, 2024 2:10 pm | Benjamin Burnett | Stifel Nicolaus | $10.00 | $7.58 | StreetInsider | Atara Biotherapeutics (ATRA) PT Raised to $10 at Stifel |
| August 16, 2024 8:55 am | Salim Syed | Mizuho Securities | $18.00 | $6.83 | TheFly | Mizuho upgrades Atara to Buy into potentially better 2025 |
| August 9, 2022 8:38 am | — | Goldman Sachs | $3.00 | $3.87 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $3 |
| May 24, 2022 7:31 am | — | Goldman Sachs | $4.00 | $4.85 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $4 |
Latest News for ATRA
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want…
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company's global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the…
NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRA.
U.S. House Trading
No House trades found for ATRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.